182 related articles for article (PubMed ID: 15086736)
1. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment.
Horn LC; Schnurrbusch U; Bilek K; Hentschel B; Einenkel J
Int J Gynecol Cancer; 2004; 14(2):348-53. PubMed ID: 15086736
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological analysis in cases with glandular and atypical glandular hyperplasia treated with gestagens].
Ivanov S
Akush Ginekol (Sofiia); 2005; 44(4):18-20. PubMed ID: 16028373
[TBL] [Abstract][Full Text] [Related]
3. Papillary proliferation of the endometrium: a clinicopathologic study of 59 cases of simple and complex papillae without cytologic atypia.
Ip PP; Irving JA; McCluggage WG; Clement PB; Young RH
Am J Surg Pathol; 2013 Feb; 37(2):167-77. PubMed ID: 23211295
[TBL] [Abstract][Full Text] [Related]
4. Incidence of endometrial carcinoma in patients with endometrial hyperplasia.
Novac L; Grigore T; Cernea N; Niculescu M; Cotarcea S
Eur J Gynaecol Oncol; 2005; 26(5):561-3. PubMed ID: 16285581
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
[TBL] [Abstract][Full Text] [Related]
6. Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings.
Mittal K; Da Costa D
Int J Gynecol Pathol; 2008 Jan; 27(1):45-8. PubMed ID: 18156974
[TBL] [Abstract][Full Text] [Related]
7. [Modern tendencies in treatment of atypical glandular hyperplasia--our and foreign experience].
Ivanov S; Kovachev E; Tsonev A; Abbud A
Akush Ginekol (Sofiia); 2010; 49(2):47-9. PubMed ID: 20734678
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia.
Hunter JE; Tritz DE; Howell MG; DePriest PD; Gallion HH; Andrews SJ; Buckley SB; Kryscio RJ; van Nagell JR
Gynecol Oncol; 1994 Oct; 55(1):66-71. PubMed ID: 7959270
[TBL] [Abstract][Full Text] [Related]
9. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding.
Anastasiadis PG; Skaphida PG; Koutlaki NG; Galazios GC; Tsikouras PN; Liberis VA
Eur J Gynaecol Oncol; 2000; 21(2):131-4. PubMed ID: 10843470
[TBL] [Abstract][Full Text] [Related]
10. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
Trimble CL; Kauderer J; Zaino R; Silverberg S; Lim PC; Burke JJ; Alberts D; Curtin J
Cancer; 2006 Feb; 106(4):812-9. PubMed ID: 16400639
[TBL] [Abstract][Full Text] [Related]
11. Clinico-epidemiological study of endometrial hyperplasia--a risk factor for the development of endometrial carcinoma?
Cărăuleanu A; Lupaşcu IA; Cărăuleanu DM; Socolov R; Socolov D
Rev Med Chir Soc Med Nat Iasi; 2015; 119(1):154-61. PubMed ID: 25970959
[TBL] [Abstract][Full Text] [Related]
12. Significance of benign endometrial cells in Pap smears from postmenopausal women.
Wu HH; Schuetz MJ; Cramer H
J Reprod Med; 2001 Sep; 46(9):795-8. PubMed ID: 11584479
[TBL] [Abstract][Full Text] [Related]
13. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
14. Use of the progestogen challenge test to reduce the risk of endometrial cancer.
Gambrell RD; Massey FM; Castaneda TA; Ugenas AJ; Ricci CA; Wright JM
Obstet Gynecol; 1980 Jun; 55(6):732-8. PubMed ID: 6446050
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia.
Shutter J; Wright TC
Int J Gynecol Pathol; 2005 Oct; 24(4):313-8. PubMed ID: 16175074
[TBL] [Abstract][Full Text] [Related]
16. Endometrial curettage in abnormal uterine bleeding and efficacy of progestins for control in cases of hyperplasia.
Mesci-Haftaci S; Ankarali H; Yavuzcan A; Caglar M
Asian Pac J Cancer Prev; 2014; 15(8):3737-40. PubMed ID: 24870785
[TBL] [Abstract][Full Text] [Related]
17. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
[TBL] [Abstract][Full Text] [Related]
18. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma.
Buell-Gutbrod R; Cavallo A; Lee N; Montag A; Gwin K
Int J Gynecol Pathol; 2015 Jan; 34(1):65-73. PubMed ID: 25473755
[TBL] [Abstract][Full Text] [Related]
19. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
[TBL] [Abstract][Full Text] [Related]
20. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
